Female obesity adversely affects assisted reproductive technology (ART) pregnancy and live birth rates

Abstract

Higher BMI is associated with an increased failure to achieve a clinical intrauterine gestation; this risk was overcome with the use of donor oocytes. Failure to achieve a live birth increases with higher BMI, significantly with the use of autologous oocytes (P< 0.0001), and to a greater extent among women <35 years of age (P< 0.0001).

Methotrexate does not affect ovarian reserve or subsequent assisted reproductive technology outcomes

“…This is similar to national data published by the Society of Assisted Reproductive Technology demonstrating a pregnancy rate per transfer of 53 % in women less than 35 years of age and 37 % in women 38-40 years [23]. Six (3.1 %) women had another ectopic pregnancy.…”

Perinatal outcomes of singleton siblings: the effects of changing maternal fertility status

“…Donor oocytes, which could only be utilized in the ART group, help to overcome the issues of older maternal age [34] and maternal obesity [35] but have been associated with greater risks for gestational hypertension and preeclampsia [36][37][38]. These hypertensive disorders, in turn, are associated with greater risks for placental abruption as well as disseminated intravascular coagulation, cerebral hemorrhage, and Adjusted 1A = maternal age in current birth, race/ethnicity, education, and infant gender in current birth; adjusted 2A = maternal age in second birth, race/ethnicity, education, infant gender in second birth, and fertility status group for first birth hepatic and renal failures [39].…”

Cumulative Birth Rates With Linked Assisted Reproductive Technology Cycles

“…15,16,20 Second, body-mass index was not considered in these analyses, since it was not included in the SART CORS database until 2007, but it is known to affect success rates. 21,22 Third, we evaluated oocyte state and oocyte source separately. In clinical practice, a patient might have successive cycles with fresh and thawed oocytes, and the oocyte source might change from autologous to donor.…”